Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria



Status:Recruiting
Conditions:Liver Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 80
Updated:10/15/2017
Start Date:August 2010
End Date:June 2018
Contact:Diane Scavone
Email:DScavone@llu.edu
Phone:909-558-3636

Use our guide to learn which trials are right for you!

Randomized Controlled Trial of Proton Beam Radiotherapy + Sorafenib vs. Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria

This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared
to Sorafenib alone will produce the best results for treating patients with Hepatocellular
Carcinoma.


Inclusion Criteria:

1. Patients are candidates to receive both proton beam and sorafenib

2. Patients with tumor burden that exceeds San Francisco criteria

Exclusion Criteria:

1. Patients who are candidates for surgical resection

2. Patients with tumor burden within Milan and/or San Francisco criteria

3. Patients who have contraindication to receive proton

4. Patients with contraindication to receive sorafenib including uncontrolled
hypertension, coumadin treatment and prior intolerability to the drug

5. Patients treated previously by any locoregional treatment

6. Patients with prior liver transplant

7. Patients with child class C

8. Patients with model for end-stage liver disease (MELD) score of > 25

9. Patients with other comorbid diseases that may impact survival

10. Patients with ongoing alcohol intake

11. Patients with active sepsis

12. Patients with gastrointestinal bleeding within a week

13. Patients unwilling to sign informed consent form

14. Patients with history of noncompliance
We found this trial at
1
site
11234 Anderson St
Loma Linda, California 92354
(909) 558-4000
Loma Linda University Medical Center An outgrowth of the original Sanitarium on the hill in...
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials